U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description

Forigerimod (also known as IPP-201101) a phosphopeptide is being investigated for the treatment of Lupus Erythematosus, Systemic. This drug is completed phase III clinical trials and is ready for licensing.

Approval Year

Unknown
139,594

PubMed

Sample Use Guides

In Vivo Use Guide
200 mcg of IPP-201101 (FORIGERIMOD) will be administered subcutaneously every 4 weeks for 24 weeks.
Route of Administration: Other
Substance Class Protein
Protein Sub Type
Sequence Type COMPLETE
Record UNII
1JRB6UKG4Q
Record Status Validated (UNII)
Record Version
Subunit 0

NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966